Background and objectives: Many mediators and
cytokines are involved in the pathogenesis of
osteoarthritis (OA). Some of these
cytokines are spontaneously expressed by cultured fibroblast-like synoviocytes. Therefore, using serum samples, the efficacy and the effects of avocado/soy unsaponifiables, ASU, (Arthrocen) on
cytokine changes were assessed in patients with knee OA (KOA). Materials and Methods: Experimental procedure: A randomized, double-blind, placebo-controlled clinical trial was conducted on patients with a diagnosis of mild to moderate OA who received either Arthrocen 300 mg/day (n = 61) or placebo (n = 58) for 3 months. Data collection was performed using questionnaires including the Western Ontario and McMaster Universities
osteoarthritis index (WOMAC), 20-item short form survey (SF-20), Lequesne index of severity for
osteoarthritis of the knee (LISOK), and three visual analog scales (VASs) as
pain quality indices. The serum levels of
interleukins 2 (IL-2),
IL-4,
IL-10, IL-17α, and TNF-α were measured using an ELISA reader. Results: Both quality of life indices,
pain sensation and scored by specialists (as VASs), respectively, including WOMAC and SF-20, as well as joint dysfunctionality symptoms assessed by physicians were significantly improved (p < 0.05) in OA patients receiving Arthrocen. The serum levels of anti-inflammatory
interleukins 4 and 10 were also augmented, while levels of inflammatory
IL-17 and TNF-ɑ
cytokines were decreased significantly (p < 0.05) compared with the control groups during the 3- and 6-month treatment. Conclusions: Arthrocen consumption may increase the quality of life in OA patients through amelioration of
inflammation and improvement of functional activities without any adverse effects in the long term.